Table 1. Clinical characteristics of the... | American Society of Hematology

Table 1.

Clinical characteristics of the 8 patients with MM included in the study

Patient no.	Sex/age, y	Disease stage, Durie-Salmon	Treatment	Ig isotype	M-protein concentration, g/L
1	Male/66	Newly diagnosed stage IIIA	NT	IgA λ	55 (plasma)
2	Male/61	Newly diagnosed stage IIA	NT	κ	50 (plasma)
3	Female/71	Clinically stable BJ	Chemotherapy refractory	κ	0.8 (urine)
4	Male/70	Newly diagnosed BJ stage IIIA	NT	λ	3.6 (urine)
5	Female/71	Newly diagnosed BJ stage IIIA	NT	κ	0.3 (urine)
6	Male/71	Newly diagnosed BJ stage IIB	NT	κ	3.3 (urine)
7	Male/83	Newly diagnosed BJ stage IIIB	NT	κ	1.4 (urine)
8	Male/78	Newly diagnosed stage IIIA	NT	IgA κ	30 (plasma)

Patient no.	Sex/age, y	Disease stage, Durie-Salmon	Treatment	Ig isotype	M-protein concentration, g/L
1	Male/66	Newly diagnosed stage IIIA	NT	IgA λ	55 (plasma)
2	Male/61	Newly diagnosed stage IIA	NT	κ	50 (plasma)
3	Female/71	Clinically stable BJ	Chemotherapy refractory	κ	0.8 (urine)
4	Male/70	Newly diagnosed BJ stage IIIA	NT	λ	3.6 (urine)
5	Female/71	Newly diagnosed BJ stage IIIA	NT	κ	0.3 (urine)
6	Male/71	Newly diagnosed BJ stage IIB	NT	κ	3.3 (urine)
7	Male/83	Newly diagnosed BJ stage IIIB	NT	κ	1.4 (urine)
8	Male/78	Newly diagnosed stage IIIA	NT	IgA κ	30 (plasma)

Terms in parentheses indicate the media in which M-proteins were measured. BJ indicates Bence-Jones MM; and NT, not treated.